Commonly reported GLP-1 adverse effectsincluding nausea, vomiting, constipation, and abdominal discomfortsubstantially overlap with symptoms of an IBD flare, which may complicate safety monitoring and clinical assessment
Semaglutide is one of the most prescribed GLP-1 receptor agonists for weight loss, yet research shows approximately 25% of patients experience minimal weight reduction despite consistent use
In 2018, total US GLP-1 spending was $57 million
GLP-1 drugs, also called GLP-1 agonists, are shortened names for glucagon-like peptide-1 receptor agonists
The reduced risk of MACE and heart failure in general from the use of SGLT2 selective inhibitors is mainly in patients with established atherosclerotic disease and does not necessarily address diabetics with multiple risk factors
7.2 A Placebo-Controlled Phase II Study of Exendin-4 (Bydureon ) in PD The encouraging outcome of the pilot study led to a placebo-controlled phase II study (NCT01971242)